Amendment: SEC Form S-4/A filed by Coeptis Therapeutics Holdings Inc.
$COEP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, , announced today that its registration statement on Form S-4 (File No. 333-288329) (as amended, the "Registration Statement"), relating to the previously announced merger transaction (the "Transaction") with Z Squared Inc. ("ZSQ"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it will commence mailing the definitive proxy statement/prospectus relating to the Annual/Special Meeting (the "Stockholder Meeting") of the Company's stockholders to be held on January 30, 2
BRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- VanderbiltReport.com, a financial news and content platform, reports that Coeptis Therapeutics (NASDAQ:COEP) is pioneering a dual-track model designed to sustain innovation while reducing reliance on dilutive funding. The biotech industry is known for high burn rates and long timelines. Companies often face an impossible choice between continuous capital raises or scaling back scientific ambitions. Coeptis is demonstrating that hybrid business models can provide a sustainable alternative. Revenue and Research Together In Q2 2025, Coeptis generated $200,681 in revenue while advancing its GEAR Cell Therapy Platform for cancer
WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd ("Yorkville"). The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company's outstanding debt obligations to Yorkville. David Mehalick, CEO of Coeptis Therapeutics Holdings, Inc., stated, "The extinguishment of these outstanding debt obligations strengthens the Company's capital structure and positions us well to pursue our long-term goals." Management notes that a streamlined capital struct
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)
424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
EFFECT - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
S-4/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat
Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.
15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in
SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)